- The Stories
- Investor Relations
- Corporate Governance
- Financial Report 2022
- Chief financial officer’s report
- Five-year consolidated data
- Consolidated financial statements
- Notes to the consolidated financial statements
- 1 Reporting entity
- 2 Summary of significant accounting policies
- 3 Scope of consolidation
- 4 Sales – Revenue from contracts with customers
- 5 Sales – Income from operating lease arrangements (group as lessor)
- 6 Segment information
- 7 Operating expenses by nature
- 8 Research and development
- 9 Other operating result
- 10 Financial result
- 11 Earnings per share
- 12 Employee benefits
- 13 Income taxes
- 14 Cash and cash equivalents
- 15 Other current financial assets
- 16 Trade accounts receivable
- 17 Inventories
- 18 Non-current financial assets
- 19 Property, plant and equipment
- 20 Right-of-use assets (group as lessee)
- 21 Intangible assets and goodwill
- 22 Financial liabilities
- 23 Contract liabilities
- 24 Government grants
- Statutory Auditor´s Report on the Consolidated Financial Statements
- Balance sheet of Tecan Group Ltd.
- Income statement of Tecan Group Ltd.
- Notes to the financial statements of Tecan Group Ltd.
- 1 Reporting entity
- 2 Summary of significant accounting policies
- 3 Investments in subsidiaries
- 4 Bond
- 5 Provision for general business risks
- 6 Shareholders’ equity
- 7 Gain on sale of financial investments
- 8 Number of employees
- 9 Number of shares and share options
- 10 Guarantees in favor of third parties
- 11 Liabilities from lease arrangements not included in the balance sheet
- 12 Subsequent events
- Statutory Auditor`s Report on the Financial Statements of Tecan Group Ltd.
- Global
24 GOVERNMENT GRANTS
| 2021 | 2022 |
CHF 1,000 |
|
|
Balance at January 1 | 16,876 | 22,391 |
Received | 5,012 | 7,960 |
Translation differences | 503 | 30 |
|
|
|
Balance at December 31 | 22,391 | 30,381 |
|
|
|
Thereof current | 3,661 | 4,170 |
Thereof non-current | 18,730 | 26,211 |
In October 2020 the U.S. Department of Defense and the U.S. Department of Health and Human Services awarded a government grant of USD 32.9 million (CHF 30.0 million) to support the buildup of a U.S. pipette tip manufacturing for COVID-19 testing. Disposable pipette tips are key components for molecular tests for SARS-CoV-2 and other assays performed on fully automated, high throughput systems.
The funding enables the Group to launch new production capacity in the U.S. and to increase the domestic supply for critical medical resources.
This government grant is related to the purchase and installation of new production lines reported in position property, plant and equipment (see note 19). The new U.S. manufacturing facility is expected to start producing pipette tips in spring 2023.
Follow Tecan